Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Movement Disorders

Volumn 13, Issue 4, 1998, Pages 673-676

  Rascol, Olivier ^a,e   Sieradzan, Kasia ^b   Peyro Saint Paul, Hélène ^c   Thalamas, Claire ^a   Brefel Courbon, Christine ^a   Senard, Jean Michel ^a   Ladure, Philippe ^c   Montastruc, Jean Louis ^a   Lees, Andrew ^d  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c Centre d'Immunologie Pierre Fabre   (France)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e INSERM   (France)

Author keywords

Alpha 2 antagonist; Clinical trial; Efaroxan; Progressive supranuclear palsy

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; EFAROXAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; BENZOFURANS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; SUPRANUCLEAR PALSY, PROGRESSIVE; TREATMENT OUTCOME;

EID: 0031853557     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130411     Document Type: Article

References (23)

1. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991;41:986-991.
2. Chapleo CB, Myers PL, Butter RCM, et al. Alpha-2 adrenoceptor agents 2. Effects of modifications of the 1,4-benzodioxan ring system on alpha adrenoreceptor activity. Journal of Medical Chemistry 1984;27:570-576.
3. Berridge TL, Doxey JC, Roach AG, Smith CFC. Selectivity profile of the alpha-2 adrenoreceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat. Eur J Pharmacol 1992;213:205-212.
4. Brown MJ. Investigation of alpha-2 adrenoreceptors in humans. Am J Med 1989;87:65-95.
5. De Vos H, De Backer JP, Vauquelin G. High affinity of two substituted idazoxan analogs and efaroxan for alpha-2 adrenergic receptors in human frontal cortex membranes. In: Szabadi E, Bradshaw CM, eds. Adrenoreceptors: Structure, Mechanisms, Function. Advances in Pharmacological Sciences. Basel: Birkhaüser Verlag, 1991:307-309.
6. Flamez A, De Backer JP, Czerwiec E, Ladure P, Vauquelin G. Pharmacological characterization of I1 and I2 imidazoline receptors in human striatum. Neurochem Int 1997;30:25-29.
7. Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S, eds. Movement Disorders, 2nd ed. London: Butterworths, 1987:272-287.
8. Diagnosis and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC: American Psychiatric Association, 1994:133-155.
9. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
10. D'Costa DF, Abbott RJ, Pye IF, Millac PAH. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991;54:870-872.
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;174:382-389.
12. National Institute of Mental Health. Clinical Global Impression. In: Guy W, ed. ECDEU (Early Clinical Drug Evaluation Unit). Assessment Manual for Psychopharmacology. Washington, DC: US Government Printing Office, 1976:218-222.
13. Armitage P, Hills M. The two-period crossover trial. The Statistician 1982;31:119-131.
14. Golbe L, Medical Advisory Board for the Society for Progressive Supranuclear Palsy. A clinical rating scale and staging system for progressive supranuclear palsy [Abstract]. Neurology 1997;48:326.
15. Doxey JC, Lane AC, Roach AG, Smith CFC, Walter DS. Selective alpha-2 adrenoreceptor agonists and antagonists. In: Szabady E, Bradshaw CM, Nahorski SR, eds. Pharmacology of Adrenoreceptors. New York, NY: MacMillan, 1985:13-22.
16. Senard JM, Durrieu G, Berlan M, et al. Absence of arterial hypertension despite chronic plasma noradrenaline elevation: evidence for down-regulation of alpha-adrenoreceptors. A case report. Fundam Clin Pharmacol 1991;5:291-298.
17. Ruzicka E, Ladure P, Roth J, Jech R, Mecir P, Peyro-Saint-Paul H. Efficacy and safety of efaroxan, an alpha-2 adrenoreceptor antagonist, in Parkinson's disease: an oral short-term study. Mov Disord 1997;125:123.
18. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996;36:511-544.
19. Tesson F, Limon-Boulez I, Urban P, et al. Localization of 12-imidazoline binding sites on monoamine oxidases. J Biochem 1995;270:9856-9861.
20. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
21. Gaspar P, Berger B, Alvarez C, Vigny A, Henry JP. Catecholamine innervation of the septal area in man. Immunocytochemical study using TH and DBH antibodies. J Comp Neurol 1985;241:12-33.
22. De Vos H, Bricca G, De Keyser J, De Backer JP, Bousquet P, Vauquelin G. Imidazoline receptors, nonadrenergic idazoxan binding sites and alpha-2 adrenoreceptors in the human central nervous system. Neuroscience 1994;59:589-598.
23. Pascual J, Berciano J, Gonzalez AM, Grijalba B, Figols J, Pazos A. Autoradiographic demonstration of loss of alpha-2 adrenoreceptors in progressive supranuclear palsy: preliminary report. J Neurol Sci 1993;114:165-169.